Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets

Cardiorenal syndrome (CRS) is a complex disorder that refers to the category of acute or chronic kidney diseases that induce cardiovascular disease, and inversely, acute or chronic heart diseases that provoke kidney dysfunction. There is a close relationship between renal and cardiovascular disease,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: José Alberto Navarro-García, Laura González-Lafuente, María Fernández-Velasco, Luis M. Ruilope, Gema Ruiz-Hurtado
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/ac6da582782d4dc9a8681efa0f0a5d0f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ac6da582782d4dc9a8681efa0f0a5d0f
record_format dspace
spelling oai:doaj.org-article:ac6da582782d4dc9a8681efa0f0a5d0f2021-11-15T06:48:27ZFibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets1664-042X10.3389/fphys.2021.775029https://doaj.org/article/ac6da582782d4dc9a8681efa0f0a5d0f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphys.2021.775029/fullhttps://doaj.org/toc/1664-042XCardiorenal syndrome (CRS) is a complex disorder that refers to the category of acute or chronic kidney diseases that induce cardiovascular disease, and inversely, acute or chronic heart diseases that provoke kidney dysfunction. There is a close relationship between renal and cardiovascular disease, possibly due to the presence of common risk factors for both diseases. Thus, it is well known that renal diseases are associated with increased risk of developing cardiovascular disease, suffering cardiac events and even mortality, which is aggravated in those patients with end-stage renal disease or who are undergoing dialysis. Recent works have proposed mineral bone disorders (MBD) as the possible link between kidney dysfunction and the development of cardiovascular outcomes. Traditionally, increased serum phosphate levels have been proposed as one of the main factors responsible for cardiovascular damage in kidney patients. However, recent studies have focused on other MBD components such as the elevation of fibroblast growth factor (FGF)-23, a phosphaturic bone-derived hormone, and the decreased expression of the anti-aging factor Klotho in renal patients. It has been shown that increased FGF-23 levels induce cardiac hypertrophy and dysfunction and are associated with increased cardiovascular mortality in renal patients. Decreased Klotho expression occurs as renal function declines. Despite its expression being absent in myocardial tissue, several studies have demonstrated that this antiaging factor plays a cardioprotective role, especially under elevated FGF-23 levels. The present review aims to collect the recent knowledge about the FGF-23-Klotho axis in the connection between kidney and heart, focusing on their specific role as new therapeutic targets in CRS.José Alberto Navarro-GarcíaLaura González-LafuenteMaría Fernández-VelascoLuis M. RuilopeLuis M. RuilopeLuis M. RuilopeGema Ruiz-HurtadoGema Ruiz-HurtadoFrontiers Media S.A.articleFGF-23Klothocardiorenal syndromechronic kidney diseaseacute kidney injurydialysisPhysiologyQP1-981ENFrontiers in Physiology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic FGF-23
Klotho
cardiorenal syndrome
chronic kidney disease
acute kidney injury
dialysis
Physiology
QP1-981
spellingShingle FGF-23
Klotho
cardiorenal syndrome
chronic kidney disease
acute kidney injury
dialysis
Physiology
QP1-981
José Alberto Navarro-García
Laura González-Lafuente
María Fernández-Velasco
Luis M. Ruilope
Luis M. Ruilope
Luis M. Ruilope
Gema Ruiz-Hurtado
Gema Ruiz-Hurtado
Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
description Cardiorenal syndrome (CRS) is a complex disorder that refers to the category of acute or chronic kidney diseases that induce cardiovascular disease, and inversely, acute or chronic heart diseases that provoke kidney dysfunction. There is a close relationship between renal and cardiovascular disease, possibly due to the presence of common risk factors for both diseases. Thus, it is well known that renal diseases are associated with increased risk of developing cardiovascular disease, suffering cardiac events and even mortality, which is aggravated in those patients with end-stage renal disease or who are undergoing dialysis. Recent works have proposed mineral bone disorders (MBD) as the possible link between kidney dysfunction and the development of cardiovascular outcomes. Traditionally, increased serum phosphate levels have been proposed as one of the main factors responsible for cardiovascular damage in kidney patients. However, recent studies have focused on other MBD components such as the elevation of fibroblast growth factor (FGF)-23, a phosphaturic bone-derived hormone, and the decreased expression of the anti-aging factor Klotho in renal patients. It has been shown that increased FGF-23 levels induce cardiac hypertrophy and dysfunction and are associated with increased cardiovascular mortality in renal patients. Decreased Klotho expression occurs as renal function declines. Despite its expression being absent in myocardial tissue, several studies have demonstrated that this antiaging factor plays a cardioprotective role, especially under elevated FGF-23 levels. The present review aims to collect the recent knowledge about the FGF-23-Klotho axis in the connection between kidney and heart, focusing on their specific role as new therapeutic targets in CRS.
format article
author José Alberto Navarro-García
Laura González-Lafuente
María Fernández-Velasco
Luis M. Ruilope
Luis M. Ruilope
Luis M. Ruilope
Gema Ruiz-Hurtado
Gema Ruiz-Hurtado
author_facet José Alberto Navarro-García
Laura González-Lafuente
María Fernández-Velasco
Luis M. Ruilope
Luis M. Ruilope
Luis M. Ruilope
Gema Ruiz-Hurtado
Gema Ruiz-Hurtado
author_sort José Alberto Navarro-García
title Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
title_short Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
title_full Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
title_fullStr Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
title_full_unstemmed Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
title_sort fibroblast growth factor-23-klotho axis in cardiorenal syndrome: mediators and potential therapeutic targets
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/ac6da582782d4dc9a8681efa0f0a5d0f
work_keys_str_mv AT josealbertonavarrogarcia fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT lauragonzalezlafuente fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT mariafernandezvelasco fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT luismruilope fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT luismruilope fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT luismruilope fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT gemaruizhurtado fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
AT gemaruizhurtado fibroblastgrowthfactor23klothoaxisincardiorenalsyndromemediatorsandpotentialtherapeutictargets
_version_ 1718428574987321344